Lumos Announces Expanded Scope of Work under Hologic fFN Development Agreement
3 March 2025
Lumos Diagnostics has announced an agreement to expand the scope of work under the Development Agreement covering the new fetal fibronectin (fFN) test for leading women’s health company, Hologic, Inc.
The expanded scope of work relates to Phase 3 of the Development Agreement, which focuses on delivery of the system prototype. This phase will now include incorporating additional hardware features into the proprietary reader technology, with an additional fee to Lumos of between US$0.6 – US$0.8 million.
Lumos Diagnostics Managing Director, Doug Ward, said:
"We are extremely pleased with the progress of the Hologic fFN project. Phase 2 of the project is progressing well and is expected to complete around April 2025, triggering the second of the Phase 2 milestone payments, worth US$0.3 million. In collaboration with the Hologic team, Phase 3 will now deliver a more feature rich product."
Click to read the ASX release.
The expanded scope of work relates to Phase 3 of the Development Agreement, which focuses on delivery of the system prototype. This phase will now include incorporating additional hardware features into the proprietary reader technology, with an additional fee to Lumos of between US$0.6 – US$0.8 million.
Lumos Diagnostics Managing Director, Doug Ward, said:
"We are extremely pleased with the progress of the Hologic fFN project. Phase 2 of the project is progressing well and is expected to complete around April 2025, triggering the second of the Phase 2 milestone payments, worth US$0.3 million. In collaboration with the Hologic team, Phase 3 will now deliver a more feature rich product."
Click to read the ASX release.
